drugset / Trial / NCT04592835
To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003
Phase 1
Unknown
24 enrolled
Daewoong Pharmaceutical Co. LTD.
Novotech (Australia) Pty Limited · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is designed to assess the safety, tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) in healthy volunteers.
Timeline
- Start
- 2020-10-19
- Primary completion
- 2020-12-13
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Niclosamide | Unknown | 288 mg | Intramuscular |
| Subject | Niclosamide | Unknown | 576 mg | Intramuscular |
| Subject | Niclosamide | Unknown | 960 mg | Intramuscular |
Indications
No indication recorded.